DexCom had 25 patents in artificial intelligence during Q2 2024. DexCom Inc’s patents in Q2 2024 focus on improving health outcomes for patients through personalized decision support outputs based on analyte levels. One patent describes using machine learning in an artificial pancreas system, where a wearable glucose monitoring device continuously measures glucose levels and an algorithm determines insulin doses to maintain glucose within a target range, with the ability to update the algorithm over time for improved effectiveness. GlobalData’s report on DexCom gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
DexCom had no grants in artificial intelligence as a theme in Q2 2024.
Recent Patents
Application: Determining decision support outputs using user-specific analyte level criteria (Patent ID: US20240172999A1)
The patent filed by DexCom Inc. describes systems, devices, and methods for improving patients' health outcomes by determining decision support outputs using user-specific analyte level criteria. The invention involves a computer program that receives sensor data from an analyte sensor, determines analyte level criteria for the user, uses a decision support model to generate decision support outputs based on the criteria, and provides these outputs to the user. The analyte level criteria can include optimal level ranges or risk tolerance profiles, allowing for personalized healthcare management.
The patent includes claims for a non-transitory computer readable storage medium storing the program, a method for determining decision support outputs, and a computing device implementing the described processes. These claims detail the steps involved in receiving sensor data, determining analyte level criteria, using a decision support model, and providing decision support outputs to the user. The criteria can be optimal level ranges or risk tolerance profiles, with thresholds for high and low analyte levels. The user can also provide input to customize these thresholds, ensuring a tailored approach to managing their health. Overall, the patent outlines a comprehensive system for leveraging analyte data to provide personalized decision support for improved health outcomes.
To know more about GlobalData’s detailed insights on DexCom, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
